Compare FEMY & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEMY | DXR |
|---|---|---|
| Founded | 2004 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.5M | 61.1M |
| IPO Year | 2021 | N/A |
| Metric | FEMY | DXR |
|---|---|---|
| Price | $0.82 | $12.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $6.83 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.4M | 2.7K |
| Earning Date | 11-14-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $2,061,502.00 | $66,306.00 |
| Revenue This Year | $64.02 | N/A |
| Revenue Next Year | $147.19 | N/A |
| P/E Ratio | ★ N/A | $35.00 |
| Revenue Growth | ★ 63.53 | N/A |
| 52 Week Low | $0.31 | $6.55 |
| 52 Week High | $1.80 | $14.15 |
| Indicator | FEMY | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 47.99 |
| Support Level | $0.79 | $12.38 |
| Resistance Level | $0.89 | $12.90 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 26.39 | 38.39 |
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.